These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20826564)

  • 1. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes.
    Morgantini C; Imaizumi S; Grijalva V; Navab M; Fogelman AM; Reddy ST
    Diabetes; 2010 Dec; 59(12):3223-8. PubMed ID: 20826564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of L-4F and simvastatin stimulate cholesterol efflux and related proteins expressions to reduce atherosclerotic lesions in apoE knockout mice.
    Ying R; Yuan Y; Qin YF; Tian D; Feng L; Guo ZG; Sun YX; Li MX
    Lipids Health Dis; 2013 Dec; 12():180. PubMed ID: 24314261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.
    Woo JM; Lin Z; Navab M; Van Dyck C; Trejo-Lopez Y; Woo KM; Li H; Castellani LW; Wang X; Iikuni N; Rullo OJ; Wu H; La Cava A; Fogelman AM; Lusis AJ; Tsao BP
    Arthritis Res Ther; 2010; 12(3):R93. PubMed ID: 20482780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
    Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice.
    Nogi Y; Nagashima M; Terasaki M; Nohtomi K; Watanabe T; Hirano T
    PLoS One; 2012; 7(4):e35683. PubMed ID: 22536426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice.
    Li X; Chyu KY; Faria Neto JR; Yano J; Nathwani N; Ferreira C; Dimayuga PC; Cercek B; Kaul S; Shah PK
    Circulation; 2004 Sep; 110(12):1701-5. PubMed ID: 15353488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse D4F, an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in ApoE-null mice.
    Qin S; Kamanna VS; Lai JH; Liu T; Ganji SH; Zhang L; Bachovchin WW; Kashyap ML
    J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):334-43. PubMed ID: 22308547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Hough G; Wagner A; Nakamura K; Garber DW; Datta G; Segrest JP; Hama S; Fogelman AM
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1100-4. PubMed ID: 14582455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
    Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.
    Nayyar G; Garber DW; Palgunachari MN; Monroe CE; Keenum TD; Handattu SP; Mishra VK; Anantharamaiah GM
    Atherosclerosis; 2012 Oct; 224(2):326-31. PubMed ID: 22771190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Lu Z; Zhang X; Li Y; Jin J; Huang Y
    J Endocrinol; 2013 Jan; 216(1):61-71. PubMed ID: 23060524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.
    Gui Y; Yao S; Yan H; Hu L; Yu C; Gao F; Xi C; Li H; Ye Y; Wang Y
    Cardiovasc Res; 2016 Oct; 112(1):502-14. PubMed ID: 27460841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exogenous Insulin Infusion Can Decrease Atherosclerosis in Diabetic Rodents by Improving Lipids, Inflammation, and Endothelial Function.
    Park K; Li Q; Evcimen ND; Rask-Madsen C; Maeda Y; Maddaloni E; Yokomizo H; Shinjo T; St-Louis R; Fu J; Gordin D; Khamaisi M; Pober D; Keenan H; King GL
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):92-101. PubMed ID: 29162603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of exogenous fibroblast growth factor 21 on atherosclerosis in apolipoprotein E deficient mice].
    Wu X; Lü Y; Fu K; Wang S; Zhao D; Peng H; Fan Q; Lü Y; Xin M; Liu J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Feb; 42(2):126-31. PubMed ID: 24735623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice.
    Li MW; Mian MO; Barhoumi T; Rehman A; Mann K; Paradis P; Schiffrin EL
    Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2306-15. PubMed ID: 23887640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic CGI-58 expression in macrophages alleviates the atherosclerotic lesion development in ApoE knockout mice.
    Xie P; Zeng X; Xiao J; Sun B; Yang D
    Biochim Biophys Acta; 2014 Dec; 1841(12):1683-90. PubMed ID: 25178844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.
    McGrath KC; Li X; Twigg SM; Heather AK
    PLoS One; 2020; 15(1):e0226931. PubMed ID: 31914125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.
    Jahagirdar R; Zhang H; Azhar S; Tobin J; Attwell S; Yu R; Wu J; McLure KG; Hansen HC; Wagner GS; Young PR; Srivastava RA; Wong NC; Johansson J
    Atherosclerosis; 2014 Sep; 236(1):91-100. PubMed ID: 25016363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
    Sherman CB; Peterson SJ; Frishman WH
    Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice.
    Wool GD; Cabana VG; Lukens J; Shaw PX; Binder CJ; Witztum JL; Reardon CA; Getz GS
    FASEB J; 2011 Jan; 25(1):290-300. PubMed ID: 20876212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.